Joincare Pharmaceutical Group Industry Co (SHSE:600380) Risk Assessment

View and export this data going back to 2001. Start your Free Trial

What is Joincare Pharmaceutical Group Industry Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Joincare Pharmaceutical Group Industry Co is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Joincare Pharmaceutical Group Industry Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Joincare Pharmaceutical Group Industry Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Joincare Pharmaceutical Group Industry Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Joincare Pharmaceutical Group Industry Co's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Joincare Pharmaceutical Group Industry Co (SHSE:600380) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Joincare Pharmaceutical Group Industry Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Joincare Pharmaceutical Group Industry Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Joincare Pharmaceutical Group Industry Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Joincare Pharmaceutical Group Industry Co Ltd (SHSE:600380) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

No. 17, Langshan Road, North District, High-tech Zone, Nanshan District, Guangdong, Shenzhen, CHN, 518057

Website

http://www.joincare.com

Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.

Executives

Xie You Guo	Supervisors
Yu Xiong	Directors, senior managers
Zhao Feng Guang	senior management
Qiu Qing Feng	Directors, senior managers
Tang Ling Zhi	senior management
Lin Nan Qi	Directors, senior managers
Cao Ping Wei	Director
Feng Yan Fang	Director
Zhong Shan	senior management
Yang Dong Yun	senior management
Peng Jin Hua	Supervisors
Guo Xiao Yun	Supervisors
Su Qing Wen	senior management

Joincare Pharmaceutical Group Industry Co Headlines

No Headlines